平特五不中

Officially launched today, is a new company aiming to advance research in opiate-sparing, pain-relieving drugs. Based on innovative research by 平特五不中 neuroscience professor Dr. Philippe S茅gu茅la, the venture is a collaboration between and . Neurasic's potential drug therapy blocks acid-sensing ion channels (ASICs), which is shown in early research to elicit analgesia (the inability to feel pain) in chronic pain conditions.

NeuroSphere, HBHL's neuroscience innovator, was key in driving this new endeavor by enabling critical partnerships between the parties involved.

鈥淗BHL is very proud to be part of Dr. S茅gu茅la鈥檚 efforts to find safer alternatives to opioids through Neurasic Therapeutics,鈥� said Krystle van Hoof, HBHL's Managing Director and CEO. 鈥淲e鈥檙e dedicated to fueling neuroscience discoveries and innovations at 平特五不中, and NeuroSphere allows HBHL to proactively ensure that critical medical breakthroughs reach patients. We will continue to proudly support Dr.聽S茅gu茅la聽and Neurasic in their efforts, and will build on this first success to help advance other ground-breaking innovations in the near future.鈥�

.